3rd Quarter - Report

MEHLMAN CONSULTING, INC. for MERCK AND CO INC

Firm
Client
Income
$40,000
Expenses
—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Budget issues, including Medicare Part D rebates and reductions in Medicare Part D low income subsidies. Discussions and possible legislation amending Title XVIII, Part D (Medicare Part D) of SSA, including issues of "non-interference clause" and Medicare Advantage. Independent Payment Advisory Board. Medicare and Entitlement Reform.

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Trade (domestic/foreign) TRD

Trans-Pacific Partnership. Biologic data exclusivity. TTIP (US-EU trade bill). Trade promotion authority. Trade with India.

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Taxation/Internal Revenue Code TAX

Tax issues: comprehensive tax reform, deferral and transfer pricing. Implementation of Budget Control Act of 2011 (Became PL 112-25 on 8-2-11). Base erosion.

LobbyistCovered position, as disclosed
KELLY RUCKER BINGEL —
DAVID CASTAGNETTI —
ELISE FINLEY PICKERING —
BRUCE MEHLMAN —
STACEY RAMPY —
DEAN ROSEN —
DAVID R THOMAS —
ALLEN L THOMPSON —
ALEX VOGEL —
BRIAN WILD —
CHARLES WOOTERS —
SUSAN ZOOK New Intern, Rep. Bill Shuster

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

H.R. 1407, Annual Drug User Fee Agreements of 2013. H. 957, S. 959, H.R. 3204, H.R. 1919, Pharmaceutical Supply Chain Security.

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 959 (113th), H.R. 1919 (113th), H.R. 3204 (113th), H.R. 1407 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.